Our Process

This online Switch Rx antidepressant tool was conceived and developed by Canadian clinician expert with the goal of providing readily accessible and up-to-date guidance to physicians in the optimal transition of patients from one antidepressant to another, or from monotherapy to combination therapy.

The content is based on published evidence, where available. However, since there are few high quality clinical trials to guide clinicians on optimal switching or augmentation strategies, some of the advice offered through this online tool is based on the expertise of of the contributing Canadian psychiatry and psychopharmacology experts, who are experienced in using psychotropic medications in the clinical setting.

Experts independently reviewed and provided their clinical input on the switching strategies suggested on this Web site. Sponsor involvement was limited to reviewing the accuracy of the information regarding theirrespective product(s).

This online SwitchRx tool is meant to serve as a guide, and in no way is it meant to replace good clinical judgment and experience. All titration schedules may be slowed down or completed more rapidly, depending on an individual patient's response and tolerance.

Recommended doses and titrations are primarily based on the respective agents' Product Monograph accessed via Health Canada's Drug Product Database. Some clinically based dose recommendations are provided, based on the collective experience and knowledge of the Expert Panel. When psychotropic medications are prescribed for patients with conditions other than unipolar depression, antidepressants might not be recommended or different target doses may be recommended and the titration schedules may differ.

Users are encouraged to contribute input regarding the content or the website itself. Feedback links can be found throughout the website once a user has logged in.

The following pharmaceutical industry sponsors have provided unrestricted grants to assist with the building and operating costs of this site: Allergan., Janssen Ortho, Lundbeck Canada Inc., Otsuka Canada Pharmaceutical Inc., Pfizer Canada Inc., Sunovion Pharmaceuticals Canada Inc.